Sarepta Therapeutics
SRPT
179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.
97% more call options, than puts
Call options by funds: $108M | Put options by funds: $54.9M
45% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 44
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
11% more capital invested
Capital invested by funds: $1.08B → $1.21B (+$123M)
2.09% more ownership
Funds ownership: 72.29% → 74.38% (+2.1%)
1% more funds holding
Funds holding: 177 → 179 (+2)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$160M |
| 2 |
HM
HealthCor Management
New York
|
+$48M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$41.8M |
| 4 |
O
OrbiMed
New York
|
+$32.6M |
| 5 |
PC
PointState Capital
New York
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$62.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$30.9M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$27.7M |
| 4 |
JG
Jefferies Group
New York
|
-$26M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.5M |
SRPT Hedge Fund Activity: Q1 2017 in Review
179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.
The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.
- 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
- Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
- 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
- The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
- The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.
Based on aggregated 13F filings for Q1 2017.